Black Diamond Therapeutics vs Kymera Therapeutics
BDTX and KYMR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDTX and KYMR compare
Kymera Therapeutics is the larger company, worth 103 times as much as Black Diamond Therapeutics ($10.5B against $102M).
Kymera Therapeutics grew revenue faster over the last twelve months (134% versus −100% for Black Diamond Therapeutics).
Kymera Therapeutics scores higher on the StockData Score (9 against 7 for Black Diamond Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDTX | KYMR |
|---|---|---|
| Size and price | ||
| Market cap | $102M | $10.5B |
| Share price | $1.78 | $126.63 |
| Change, 1 year | −53.4% | 111% |
| Change, 5 years | −77.9% | 95.0% |
| Beta (5Y) | 2.50 | 1.97 |
| Employees | 21 | 238 |
| StockData Score | ||
| Total score | 7 | 9 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 103× |
| P/B | 1.1× (better) | 6.5× |
| FCF yield | – | −2.7% |
| Fair value | – | $38.85 |
| Margin of safety | – | −226% |
| Growth | ||
| Revenue growth (TTM) | −100% | 134% (better) |
| Revenue growth, 5Y average | – | 2.9% |
| Net income growth (TTM) | −395% | – |
| EPS growth (TTM) | −422% | – |
| Profitability | ||
| Gross margin | – | 0.00% |
| Operating margin | – | −396% |
| Net margin | – | −342% |
| FCF margin | – | −283% |
| Return on equity | −37.2% | −27.3% (better) |
| Return on invested capital | – | −59.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 7.28 | 11.13 (better) |
| Altman Z-score | −3.71 | 40.23 (better) |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 61.0% | 117% |
| Held by insiders | 9.1% | 39.4% |
| Insider net buying, 12 months | – | −$297M |
| Short interest, % of float | 9.1% | 19.7% |
Go deeper
- BDTX stock overview
- BDTX income statement
- BDTX valuation and score
- KYMR stock overview
- KYMR income statement
- KYMR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.